Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Entresto | sacubitril/valsartan | Heart failure, NYHA Class II or III | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ajovy | fremanezumab | migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nexplanon | etonogestrel | Prevention of pregnancy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
| pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 4, 2024